Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors

J Immunol. 2012 Oct 1;189(7):3397-403. doi: 10.4049/jimmunol.1201540. Epub 2012 Aug 22.

Abstract

CD8(+) T cells have the potential to attack and eradicate cancer cells. The efficacy of therapeutic vaccines against cancer, however, lacks defined immune correlates of tumor eradication after (therapeutic) vaccination based on features of Ag-specific T cell responses. In this study, we examined CD8(+) T cell responses elicited by various peptide and TLR agonist-based vaccine formulations in nontumor settings and show that the formation of CD62L(-)KLRG1(+) effector-memory CD8(+) T cells producing the effector cytokines IFN-γ and TNF predicts the degree of therapeutic efficacy of these vaccines against established s.c. tumors. Thus, characteristics of vaccine-induced CD8(+) T cell responses instill a predictive determinant for the efficacy of vaccines during tumor therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / virology
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Female
  • Human papillomavirus 16 / immunology*
  • Immunologic Memory*
  • Injections, Subcutaneous
  • Mice
  • Mice, Congenic
  • Mice, Inbred C57BL
  • Molecular Sequence Data
  • Papillomavirus E7 Proteins / administration & dosage*
  • Papillomavirus E7 Proteins / immunology*
  • Papillomavirus E7 Proteins / therapeutic use
  • Predictive Value of Tests
  • Tumor Cells, Cultured
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology
  • Viral Vaccines / therapeutic use*

Substances

  • Cancer Vaccines
  • Papillomavirus E7 Proteins
  • Viral Vaccines
  • oncogene protein E7, Human papillomavirus type 16